Abstract
We show that in melanoma cells oncogenic BRAF, acting through MEK and the transcription factor BRN2, downregulates the cGMP-specific phosphodiesterase PDE5A. Although PDE5A downregulation causes a small decrease in proliferation, its major impact is to stimulate a dramatic increase in melanoma cell invasion. This is because PDE5A downregulation leads to an increase in cGMP, which induces an increase in cytosolic Ca(2+), stimulating increased contractility and inducing invasion. PDE5A downregulation also this leads to an increase in short-term and long-term colonization of the lungs by melanoma cells. We do not observe this pathway in NRAS mutant melanoma or BRAF mutant colorectal cells. Thus, we show that in melanoma cells oncogenic BRAF induces invasion through downregulation of PDE5A.
Copyright © 2011 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Calcimycin / pharmacology
-
Calcium / antagonists & inhibitors
-
Calcium / metabolism
-
Cardiac Myosins / antagonists & inhibitors
-
Cardiac Myosins / metabolism
-
Cell Line, Tumor
-
Cell Movement / drug effects
-
Cell Movement / genetics
-
Cell Proliferation
-
Cyclic GMP / analogs & derivatives
-
Cyclic GMP / metabolism
-
Cyclic GMP / pharmacology
-
Cyclic Nucleotide Phosphodiesterases, Type 5 / genetics
-
Cyclic Nucleotide Phosphodiesterases, Type 5 / metabolism*
-
Down-Regulation / genetics*
-
Gene Expression / drug effects
-
Gene Expression / genetics
-
Gene Expression Regulation, Neoplastic / drug effects
-
Gene Expression Regulation, Neoplastic / physiology*
-
Heterocyclic Compounds, 4 or More Rings / pharmacology
-
Homeodomain Proteins / metabolism
-
Humans
-
Lung Neoplasms / pathology
-
Lung Neoplasms / prevention & control
-
Lung Neoplasms / secondary
-
Melanoma / metabolism
-
Melanoma / pathology*
-
Mice
-
Mice, Nude
-
Myosin Light Chains / antagonists & inhibitors
-
Myosin Light Chains / metabolism
-
Neoplasm Invasiveness / pathology
-
Neoplasm Invasiveness / prevention & control
-
POU Domain Factors / metabolism
-
Phosphodiesterase 5 Inhibitors / pharmacology
-
Phosphorylation / drug effects
-
Promoter Regions, Genetic / genetics
-
Protein Binding / genetics
-
Protein Kinase Inhibitors / pharmacology
-
Proto-Oncogene Proteins B-raf / antagonists & inhibitors
-
Proto-Oncogene Proteins B-raf / genetics
-
Proto-Oncogene Proteins B-raf / metabolism*
-
RNA, Small Interfering / genetics
-
Transplantation, Heterologous / pathology
Substances
-
Heterocyclic Compounds, 4 or More Rings
-
Homeodomain Proteins
-
Myosin Light Chains
-
POU Domain Factors
-
Phosphodiesterase 5 Inhibitors
-
Protein Kinase Inhibitors
-
RNA, Small Interfering
-
myosin light chain 2
-
transcription factor Brn-2
-
blebbistatin
-
Calcimycin
-
BRAF protein, human
-
Proto-Oncogene Proteins B-raf
-
Cyclic Nucleotide Phosphodiesterases, Type 5
-
PDE5A protein, human
-
Cardiac Myosins
-
Cyclic GMP
-
Calcium